Trials / Recruiting
RecruitingNCT07111507
A Study of Tarlatamab for People With Prostate Cancer
TIDAL: Phase 2 Study of Tarlatamab in Patients With Delta-like Protein 3 (DLL3) Positive Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarlatamab | Patients receive lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles. |
Timeline
- Start date
- 2025-07-31
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
- First posted
- 2025-08-08
- Last updated
- 2026-04-15
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07111507. Inclusion in this directory is not an endorsement.